Genetic polymorphism of mephenytoin p(4')-hydroxylation: difference between Orientals and Caucasians.
Metoprolol and mephenytoin oxidation polymorphisms in Far Eastern Oriental subjects: Japanese versus mainland Chinese.
Genetic tests which identify the principal defects in CYP2C19 responsible for the polymorphism in mephenytoin metabolism.
Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations.
Bantu Tanzanians have a decreased capacity to metabolize omeprazole and mephenytoin in relation to their CYP2C19 genotype.
Mephenytoin hydroxylation deficiency in Caucasians: frequency of a new oxidative drug metabolism polymorphism.
An additional defective allele, CYP2C19*5, contributes to the S mephenytoin
poor metabolizer phenotype in Caucasians.
Recent studies have shown that CYP2C19 is the enzyme primarily responsible for the 4'-hydroxylation of mephenytoin in humans [60,61].
One recent study on the causes of drug-induced hepatitis revealed a relation between Atrium[R] (a combination preparation of phenobarbital, febarbamate, and difebarbamate)-induced hepatitis and the PM phenotype of mephenytoin hydroxylase X68].
Debrisoquin and mephenytoin hydroxylation phenotypes and CYP2D6 genotype in patients treated with neuroleptic and antidepressant agents.
Imipramine metabolism in relation to the sparteine and mephenytoin oxidation polymorphisms--a population study.
Hydroxylation polymorphisms of debrisoquin and mephenytoin in European populations.